Clayton Utz acts for Tattarang on its investment in ASX-listed Emyria Limited

Clayton Utz is acting for Tattarang, one of Australia's largest private investment groups, on its investment in ASX-listed, Emyria Limited (ASX: EMD). The transaction was announced to the market today.

Perth-based Corporate partner Mark Paganin and special counsel Stephen Neale are leading our team working alongside Tattarang's team, with support from lawyer Hannah Kim.

Tattarang's $5 million investment into Emyria will take the form of a share placement, under which Tattarang will be issued 20 million shares at an issue price of $0.25 per share and 10 million options. Following completion of the placement, Tattarang will hold approximately 7.3% of Emyria.

Emyria is focused on accelerating treatment development and improving patient care. Its treatments target unmet needs and are focused on obtaining approval from major global regulators.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).